Eosinophilic Asthma Clinical Trial
Official title:
A Single-blind (Patient-blind), Randomized, Placebo-controlled, Intranasal Administration Study on Mechanisms and Potential Efficacy of AD17002 in Subjects With Poorly Controlled, Moderate to Severe Eosinophilic Asthma
This clinical trial aims to investigate patients with poorly controlled, moderate to severe eosinophilic asthma. The main questions it aims to answer are 1. Could the LTh(αK) intranasal treatment improve the clinical condition of these patients? 2. Could patients self-administrate LTh(αK) via the intranasal route? 3. Is the LTh(αK) at multiple doses safe for asthmatic patients? 4. Participants will be asked to self-administrate two doses per week for a total of 6 weeks (11 doses). A diary on LTh(αK) usage, adverse events, and reliever medication will be recorded.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | September 27, 2024 |
Est. primary completion date | June 28, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Subject 20-80 years of age on the day of signing informed consent 2. Subject who is not a current smoker with poorly controlled, moderate to severe eosinophilic asthma based on GINA 2022 criteria. 3. The subject is diagnosed with asthma. 4. Subjects who have the post-bronchodilator reversibility of Forced expiratory volume 1 (FEV1) of = 12% and = 200 mL in response to a SABA at the screening visit or documented in the medical chart within 3 months of the screening visit. 5. Subjects who have =3% eosinophil counts in the induced sputum within 7 days of Visit 1. 6. Subjects with ACT scores = 19 under regular low to moderate-dose inhaled corticosteroids (ICS) and/or a combination with inhaled long-acting beta 2 agonists for at least 3 months before the Screening Visit. 7. Have a negative serum pregnancy test at the screening, and randomization visits (female subjects of childbearing potential). A female subject who is of reproductive potential agrees to remain abstinent or use (or have their partner use) an acceptable method of birth control within the projected duration of the trial. Acceptable birth control methods are intrauterine devices, hormonal contraception, diaphragm with spermicide, contraceptive sponge, condoms, and vasectomy, as per local regulations or guidelines. 8. A female subject who is not of reproductive potential is eligible without requiring the use of contraception. A female subject who is not of reproductive potential is defined as one who has either 9. Reached natural menopause (defined as 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone levels in the postmenopausal range as determined by the laboratory, or 12 months of spontaneous amenorrhea), 10. Six weeks postsurgical documented total hysterectomy and/or bilateral salpingo-oophorectomy, or 11. Bilateral tubal ligation. 12. Subject or the subject's legal representative understands the trial procedures, alternative treatments available, and risks involved with the trial, and voluntarily agrees to participate by giving written informed consent. 13. Provide written informed consent for the trial and be willing to adhere to dose and visit schedules. Exclusion Criteria: 1. Subjects with serious underlying chronic illness or severe systemic disease, including SLE, malignant diseases, uremia and heart failure, or abnormal liver function. 2. Subjects without a recent respiratory tract infection within 3 weeks before the study. 3. Subjects without a recent COVID-19 infection within 1 month before study. 4. Subjects with clinically important lung disease, including but not limited to COPD (Chronic Obstructive Pulmonary Disease), chronic respiratory infection, lung cancer, etc. 5. Arrhythmia, myocardial infarction, or stroke in the last 3 months. 6. Active COVID-19 disease (SARS-CoV-2 Lateral flow tests (LFA)-positive) at Screening. 7. A clinical history of persistent allergic asthma or rhinitis caused by an allergen to which the subject is regularly exposed and sensitized. 8. A clinical history of active chronic sinusitis (> 3 months). 9. Any clinically relevant chronic disease (>=3 months duration) (e.g. cystic fibrosis, malignancy, renal or hepatic insufficiency). 10. Subject with a documented history of Bell's palsy. 11. The subject has any nasal condition that could confound the efficacy or safety assessments. 12. Immunosuppressive treatment (ATC code L04 or L01) within 3 months before the screening visit (except the specified concomitant medications for allergy and asthma symptoms). 13. Has unstable or severe asthma, as judged by the clinical Investigator, or a subject who has experienced a life-threatening asthma attack or an occurrence of any clinical deterioration of asthma that resulted in emergency treatment, hospitalization due to asthma, or treatment with systemic corticosteroids (but allowing SABA) at any time within the last 3 months before Screening Visit. 14. Has asthma requiring high-dose oral corticosteroid (OCS) within the last 3 months before Screening Visit. 15. Has a history of anaphylaxis with cardiorespiratory symptoms with prior immunotherapy, unknown cause, or inhalant allergen. 16. Is pregnant or expecting to conceive within the projected duration of the trial. 17. Is nursing at randomization and within the projected duration of the trial? 18. Has had previous exposure to the study drug or Flu Vaccine AD07030. 19. The subject is receiving ongoing treatment with any specific immunotherapy at the time of the Screening Visit. 20. Has a known history of allergy, hypersensitivity, or intolerance to investigational medicinal products, rescue medications, or self-injectable epinephrine. |
Country | Name | City | State |
---|---|---|---|
Taiwan | Taipei Medical University Hospital | Taipei |
Lead Sponsor | Collaborator |
---|---|
Advagene Biopharma Co. Ltd. | Taipei Medical University Hospital |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | FEV1 improvement | Lung function tests with spirometry | Day 1 to Day 78 | |
Secondary | Change to the use of Short-Acting Beta Agonists (SABA) | The number of use of rescue Short-Acting Beta Agonists | Day 1 to Day 78 | |
Secondary | Fractional exhaled nitric oxide (FeNO) change | Change to the FeNO levels | Day 1 to Day 78 | |
Secondary | Sputum eosinophil change | Change to the induced sputum eosinophils' count | Day 1 to Day 78 | |
Secondary | Asthma Control Test (ACT) scores improvement | Change to the ACT scores. A maximum score of 25 points indicates complete asthma control. A score between 20 and 25 represents well controlled asthma, while a score of 19 or below represents not well controlled asthma, and a score less than 16 indicates very poorly controlled asthma. | Day 1 to Day 78 | |
Secondary | Corticosteroid used to control asthma | Numbers of corticosteroid used, inhaled or oral | Day 1 to Day 78 | |
Secondary | Immunological biomarkers of sputum | Changes in the concentration of sputum IL-4, -5, -13, IFN-a, eosinophil peroxidase (EPO), eosinophil cationic protein (ECP) from the baseline | Day 1 to Day 78 | |
Secondary | Immunological biomarkers of serum | Change of concentration from baseline of induced serum IL-4, -5, -13 | Day 1 to Day 78 | |
Secondary | Peripheral eosinophil count | Change of cell numbers from baseline of peripheral eosinophil count | Day 1 to Day 78 | |
Secondary | Adverse events_clinical visit | Clinical visit and check up by physicians | Day 1 to Day 36 and Day 78 | |
Secondary | Adverse events-Diary | Patient self report adverse events via diary | Day 1 to Day 78 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05398133 -
Phenotype Assessment of Blood and Airway Eosinophils in Patients With COPD and Asthma
|
||
Recruiting |
NCT04585997 -
Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma - "Choosebetweenamab".
|
Phase 4 | |
Completed |
NCT03563521 -
Identifying Serum Cytokine Profiles of Distinct Inflammatory Phenotypes in Severe Asthma
|
||
Completed |
NCT03469934 -
Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma
|
Phase 2 | |
Enrolling by invitation |
NCT06388889 -
Phase III Long-Term Extension Study With Dexpramipexole
|
Phase 3 | |
Recruiting |
NCT04187976 -
Eosinophils Endotypes in Chronic Airway Inflammatory Diseases
|
||
Recruiting |
NCT05813288 -
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)
|
Phase 3 | |
Completed |
NCT01285323 -
A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma
|
Phase 3 | |
Completed |
NCT03696914 -
Intense Airway Eosinophilia in Asthma
|
||
Terminated |
NCT01290887 -
Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma
|
Phase 3 | |
Recruiting |
NCT04228588 -
A Pragmatic Study to Investigate the Efficacy and Safety of Mepolizumab in Severe Uncontrolled Asthma in Brazil
|
Phase 4 | |
Recruiting |
NCT05763121 -
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.
|
Phase 3 | |
Recruiting |
NCT05748600 -
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma
|
Phase 3 | |
Completed |
NCT01508936 -
Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma
|
Phase 3 | |
Recruiting |
NCT04538937 -
Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying and Characterizing Eosinophils
|
||
Completed |
NCT05002621 -
Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma
|
||
Completed |
NCT01270464 -
A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma
|
Phase 3 | |
Completed |
NCT04674137 -
XC8 in the Treatment of Patients With the Eosinophilic Phenotype of Bronchial Asthma
|
Phase 2 | |
Recruiting |
NCT04671446 -
Identification of Autoantigens in EGPA and Severe Eosinophilic Asthma
|
||
Completed |
NCT04046939 -
Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma
|
Phase 2 |